NeoDynamics' innovative cancer treatment featured in Swedish science television program "Vetenskapens Värld"
(Thomson Reuters ONE) -
In "Vetenskapens Värld" April 4, 2011, there was a NeoDynamics feature showing
its innovative and cost-effective treatment of breast cancer. The concept has
been proven simple and reliable in in-vitro tests, and a first clinical study
with excellent results has been conducted at Capio St. Görans and Danderyds
Hospital in Stockholm. As of today, around 50 patients have been treated.
With combined knowledge and experience in both medical engineering and clinical
practice, NeoDynamics has developed a novel method to treat breast cancer in a
revolutionary cost-effective way. This patented minimally-invasive technique
uses radio frequency energy (Preferential Radio Frequency Ablation, PRFA) to
locally heat up tumor tissue and denaturize cancer cells. It is designated to
treat both benign and malignant tumors in an early stage when they have not
evolved beyond walnut size, the procedure only requires local anesthesia.
Furthermore, NeoDynamics' research has shown that this treatment preferentially
targets cancerous cells, resulting in the ability to treat tumor strands as well
as to leave healthy fatty tissue unaffected and at the same time prevent
spreading of cancer cells (anti-seeding) in the blood stream.
For the full feature, available in Sweden (about 24 min into the program),
please visit: http://svtplay.se/t/102814/vetenskapens_varld
For further information, please contact:
Prof. Hans Wiksell, Head of R&D
mobile +46 (0) 705 64 40 30
About Neodynamics
NeoDynamics is a Swedish medical technology company developing equipment to
diagnose and treat breast cancer on the same day. The company's technologies for
diagnosis and treatment are currently undergoing clinical trials. NeoDynamics'
goal is to develop further prototypes for clinical use and enter partnerships
that ensure commercialisation and global expansion.www.neodynamics.se
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class research into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP these to
the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out licensing of
products. This will result in upfront payments, milestone payments and
royalties.
An exclusive deal flow agreement with Karolinska Institutet Innovations AB,
along with other cooperation agreements with leading Nordic universities,
delivers a continuous flow of innovations.
Karolinska Development's flexible exit strategy enables projects to be exited at
whichever stage of development offers the greatest return on investment, usually
after Phase II clinical trials have indicated the desired pharmaceutical effect
on patients - this being an important value enhancing step.
Today, the portfolio consists of over 40 projects at various stages, from
concept development to Phase II clinical trials, twelve projects are in clinical
trials with six in Phase II. The portfolio is particularly strong in the areas
of cancer, dermatology, inflammation, cardiovascular disease, women's health and
diseases that affect the central nervous system. www.karolinskadevelopment.com
News Release as PDF:
http://hugin.info/143071/R/1504155/439068.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1504155]
Unternehmensinformation / Kurzprofil:
Datum: 06.04.2011 - 18:43 Uhr
Sprache: Deutsch
News-ID 53238
Anzahl Zeichen: 4357
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 166 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NeoDynamics' innovative cancer treatment featured in Swedish science television program "Vetenskapens Värld""
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
